News | July 04, 2025
Lupin launches nasal spray in US
Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals
Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
A triple-action Formula for comprehensive respiratory relief
Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery
mRNA-1010 demonstrated superior relative vaccine efficacy
Lyfius Pharma restarts operations at Penicillin-G manufacturing facility
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation in adults
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
Subscribe To Our Newsletter & Stay Updated
